Skip to main content
SpringerLink
Log in

Mucormycosis

  • Chapter
  • First Online:
Principles and Practice of Transplant Infectious Diseases

Abstract

Mucormycosis (formerly known as zygomycosis) is a life-threatening infection caused by fungi of the order Mucorales. Mucormycosis is an infectious emergency that typically occurs in patients with defects in host defense and/or with increased available serum iron, but can also occur after traumatic implantation of the etiologic fungi through skin. Recent years have witnessed some dramatic changes in the fungal taxonomy, etiology, epidemiology, and therapy of and outcomes from such infections, including in the transplant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hibbett DS, Binder M, Bischoff JF, Blackwell M, Cannon PF, Eriksson OE, et al. A higher-level phylogenetic classification of the Fungi. Mycolog Res. 2007;111(Pt 5):509–47.

    Article  Google Scholar 

  2. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, −Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24(2):411–45.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.

    Article  PubMed  Google Scholar 

  5. Cohen-Abbo A, Bozeman PM, Patrick CC. Cunninghamella infections: review and report of two cases of Cunninghamella pneumonia in immunocompromised children. Clin Infect Dis. 1993;17(2):173–7.

    Article  CAS  PubMed  Google Scholar 

  6. Kwon-Chung KJ, Young RC, Orlando M. Pulmonary mucormycosis caused by Cunninghamella elegans in a patient with chronic myelogenous leukemia. Am J Clin Pathol. 1975;64(4):544–8.

    Article  CAS  PubMed  Google Scholar 

  7. Kontoyianis DP, Vartivarian S, Anaissie EJ, Samonis G, Bodey GP, Rinaldi M. Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. Clin Infect Dis. 1994;18(6):925–8.

    Article  CAS  PubMed  Google Scholar 

  8. Ventura GJ, Kantarjian HM, Anaissie E, Hopfer RL, Fainstein V. Pneumonia with Cunninghamella species in patients with hematologic malignancies. A case report and review of the literature. Cancer. 1986;58(7):1534–6.

    Article  CAS  PubMed  Google Scholar 

  9. Bearer EA, Nelson PR, Chowers MY, Davis CE. Cutaneous zygomycosis caused by Saksenaea vasiformis in a diabetic patient. J Clin Microbiol. 1994;32(7):1823–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Lye GR, Wood G, Nimmo G. Subcutaneous zygomycosis due to Saksenaea vasiformis: rapid isolate identification using a modified sporulation technique. Pathology. 1996;28(4):364–5.

    Article  CAS  PubMed  Google Scholar 

  11. Kemna ME, Neri RC, Ali R, Salkin IF. Cokeromyces recurvatus, a mucoraceous zygomycete rarely isolated in clinical laboratories. J Clin Microbiol. 1994;32(3):843–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Kamalam A, Thambiah AS. Cutaneous infection by Syncephalastrum. Sabouraudia. 1980;18(1):19–20.

    Article  CAS  PubMed  Google Scholar 

  13. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis. 1998;27(5):1138–47.

    Article  CAS  PubMed  Google Scholar 

  14. Hotchi M, Okada M, Nasu T. Present state of fungal infections in autopsy cases in Japan. Am J Clin Pathol. 1980;74(4):410–6.

    Article  CAS  PubMed  Google Scholar 

  15. Tietz HJ, Brehmer D, Janisch W, Martin H. Incidence of endomycoses in the autopsy material of the Berlin Charite Hospital. Mycoses. 1998;41(Suppl 2):81–5.

    Article  PubMed  Google Scholar 

  16. Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol. 1999;37(6):1732–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 2014;20(7):1163–9.

    Article  Google Scholar 

  18. Nussbaum ES, Hall WA. Rhinocerebral mucormycosis: changing patterns of disease. Surg Neurol. 1994;41(2):152–6.

    Article  CAS  PubMed  Google Scholar 

  19. Maertens J, Demuynck H, Verbeken EK, Zachee P, Verhoef GE, Vandenberghe P, Boogaerts MA. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Dermatology, Bone Marrow Transplant. 1999;24(3):307–12.

    Google Scholar 

  20. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350(9):950–2.

    Article  CAS  PubMed  Google Scholar 

  21. Xhaard A, Lanternier F, Porcher R, Dannaoui E, Bergeron A, Clement L, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). Clin Microbiol Infect. 2012;18(10):E396–400.

    Article  CAS  PubMed  Google Scholar 

  22. Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, Lortholary O. Healthcare-associated mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S44–54.

    Article  PubMed  Google Scholar 

  23. Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54(11):1629–36.

    Article  Google Scholar 

  24. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis in France: the RetroZygo study (2005-2007). Clin Infect Dis. 2012;54(Suppl 1):S35–43.

    Article  CAS  PubMed  Google Scholar 

  25. Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis. 2010;16(9):1456–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Chakrabarti A, Das A, Sharma A, Panda N, Das S, Gupta KL, Sakhuja V. Ten years’ experience in zygomycosis at a tertiary care centre in India. J Infect. 2001;42(4):261–6.

    Article  CAS  PubMed  Google Scholar 

  27. Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44(4):335–42.

    Article  PubMed  Google Scholar 

  28. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39(4):584–7.

    Article  PubMed  Google Scholar 

  29. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis. 2004;39(4):588–90.

    Article  PubMed  Google Scholar 

  30. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909–17.

    Article  PubMed  Google Scholar 

  31. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851–6.

    Article  CAS  PubMed  Google Scholar 

  32. Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ, Andes DR, et al. Invasive non-aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis. 2011;17(10):1855–64.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11.

    Article  PubMed  Google Scholar 

  34. Pavie J, Lafaurie M, Lacroix C, Marie Zagdanski A, Debrosse D, Socie G, et al. Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy. Scand J Infect Dis. 2004;36(10):767–9.

    Article  PubMed  Google Scholar 

  35. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant. 2006;6(10):2365–74.

    Article  CAS  PubMed  Google Scholar 

  36. Rickerts V, Bohme A, Just-Nubling G. Risk factor for invasive zygomycosis in patients with hematologic malignancies. Mycoses. 2002;45(Suppl 1):27–30.

    Article  PubMed  Google Scholar 

  37. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39(5):743–6.

    Article  PubMed  Google Scholar 

  38. Ide L, Buysschaert I, Demuynck H, De Man R, Verlinde A, De Laere E, Surmont I. Zygomycosis in neutropenic patients with past aspergillus infection: a role for posaconazole? Clin Microbiol Infect. 2004;10(9):862–3.

    Article  CAS  PubMed  Google Scholar 

  39. Vigouroux S, Morin O, Moreau P, Mechinaud F, Morineau N, Mahe B, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis. 2005;40(4):e35–7.

    Article  PubMed  Google Scholar 

  40. Morrison VA, McGlave PB. Mucormycosis in the BMT population. Bone Marrow Transplant. 1993;11(5):383–8.

    CAS  PubMed  Google Scholar 

  41. Alsuwaida K. Primary cutaneous mucormycosis complicating the use of adhesive tape to secure the endotracheal tube. Can J Anaesth. 2002;49(8):880–2.

    Article  PubMed  Google Scholar 

  42. Petrikkos G, Skiada A, Sambatakou H, Toskas A, Vaiopoulos G, Giannopoulou M, Katsilambros N. Mucormycosis: ten-year experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis. 2003;22(12):753–6.

    Article  CAS  PubMed  Google Scholar 

  43. Adam RD, Hunter G, DiTomasso J, Comerci G Jr. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis. 1994;19(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  44. Kerr OA, Bong C, Wallis C, Tidman MJ. Primary cutaneous mucormycosis masquerading as pyoderma gangrenosum. Br J Dermatol. 2004;150(6):1212–3.

    Article  CAS  PubMed  Google Scholar 

  45. Quinio D, Karam A, Leroy JP, Moal MC, Bourbigot B, Masure O, et al. Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol. 2004;42(2):177–80.

    Article  CAS  PubMed  Google Scholar 

  46. Gartenberg G, Bottone EJ, Keusch GT, Weitzman I. Hospital-acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: epidemiology, mycology and treatment. N Engl J Med. 1978;299(20):1115–8.

    Article  CAS  PubMed  Google Scholar 

  47. Mead JH, Lupton GP, Dillavou CL, Odom RB. Cutaneous Rhizopus infection. Occurrence as a postoperative complication associated with an elasticized adhesive dressing. JAMA. 1979;242(3):272–4.

    Article  CAS  PubMed  Google Scholar 

  48. Teal LJ, Schultz KM, Weber DJ, Gergen MF, Miller MB, DiBiase LM, et al. Invasive cutaneous Rhizopus infections in an immunocompromised patient population associated with hospital laundry carts. Infect Control Hosp Epidemiol. 2016;37(10):1251–3.

    Article  PubMed  Google Scholar 

  49. Duffy J, Harris J, Gade L, Sehulster L, Newhouse E, O’Connell H, et al. Mucormycosis outbreak associated with hospital linens. Pediatr Infect Dis J. 2014;33(5):472–6.

    Article  PubMed  Google Scholar 

  50. Maravi-Poma E, Rodriguez-Tudela JL, de Jalon JG, Manrique-Larralde A, Torroba L, Urtasun J, et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med. 2004;30(4):724–8.

    Article  PubMed  Google Scholar 

  51. Singh N, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis. 2009;200(6):1002–11.

    Article  PubMed  Google Scholar 

  52. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23–34.

    Article  PubMed  Google Scholar 

  54. Sun HY, Aguado JM, Bonatti H, Forrest G, Gupta KL, Safdar N, et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant. 2009;9(9):2166–71.

    Article  PubMed  Google Scholar 

  55. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41(1):60–6.

    Article  PubMed  Google Scholar 

  56. Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2(4):348–55.

    Article  PubMed  Google Scholar 

  57. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis. 2009;199(9):1399–406.

    Article  CAS  PubMed  Google Scholar 

  58. Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120(6):1914–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Lutterloh EC, Opal SM, Pittman DD, Keith JC Jr, Tan XY, Clancy BM, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care. 2007;11(6):R122.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest. 2004;113(11):1641–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Ramsgaard L, Englert JM, Manni ML, Milutinovic PS, Gefter J, Tobolewski J, et al. Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice. PLoS One. 2011;6(5):e20132.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. C R, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, Spellberg B. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.

    Article  CAS  Google Scholar 

  63. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–9.

    Article  PubMed  Google Scholar 

  64. Boelaert JR, de Locht M, Van Cutsem J, Kerrels V, Cantinieaux B, Verdonck A, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Investig. 1993;91(5):1979–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Van Cutsem J, Boelaert JR. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int. 1989;36(6):1061–8.

    Article  PubMed  Google Scholar 

  66. Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117(9):2649–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012;50(6):611–8.

    Article  PubMed  Google Scholar 

  68. Daly AL, Velazquez LA, Bradley SF, Kauffman CA. Mucormycosis: association with deferoxamine therapy. Am J Med. 1989;87(4):468–71.

    Article  CAS  PubMed  Google Scholar 

  69. Boelaert JR, de Locht M, Schneider YJ. The effect of deferoxamine on different zygomycetes. J Infect Dis. 1994;169(1):231–2.

    Article  CAS  PubMed  Google Scholar 

  70. Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 1994;45(3):667–71.

    Article  CAS  PubMed  Google Scholar 

  71. Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D'Souza O. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol. 2003;51(3):231–6.

    PubMed  Google Scholar 

  72. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope. 1997;107(7):855–62.

    Article  CAS  PubMed  Google Scholar 

  73. Khor BS, Lee MH, Leu HS, Liu JW. Rhinocerebral mucormycosis in Taiwan. J Microbiol Immunol Infect. 2003;36(4):266–9.

    PubMed  Google Scholar 

  74. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57(4):1044–50.

    Article  CAS  PubMed  Google Scholar 

  75. Reid VJ, Solnik DL, Daskalakis T, Sheka KP. Management of bronchovascular mucormycosis in a diabetic: a surgical success. Ann Thorac Surg. 2004;78(4):1449–51.

    Article  PubMed  Google Scholar 

  76. Asai K, Suzuki K, Takahashi T, Ito Y, Kazui T, Kita Y. Pulmonary resection with chest wall removal and reconstruction for invasive pulmonary mucormycosis during antileukemia chemotherapy. Jpn J Thorac Cardiovasc Surg. 2003;51(4):163–6.

    Article  PubMed  Google Scholar 

  77. McDermott NE, Barrett J, Hipp J, Merino MJ, Richard Lee CC, Waterman P, et al. Successful treatment of periodontal mucormycosis: report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(3):e64–9.

    Article  PubMed  Google Scholar 

  78. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26(6):1383–96.

    Article  CAS  PubMed  Google Scholar 

  79. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma. 2004;45(7):1351–60.

    Article  CAS  PubMed  Google Scholar 

  80. Ruping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Florl C, Beisel C, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010;65(2):296–302.

    Article  CAS  PubMed  Google Scholar 

  81. Pagano L, Valentini CG, Posteraro B, Girmenia C, Ossi C, Pan A, et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother. 2009;21(3):322–9.

    Article  CAS  PubMed  Google Scholar 

  82. Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5–26.

    Article  CAS  PubMed  Google Scholar 

  83. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182(1):274–82.

    Article  CAS  PubMed  Google Scholar 

  84. Ibrahim AS, Gebremariam T, Husseiny MI, Stevens DA, Fu Y, Edwards JE Jr, Spellberg B. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother. 2008;52(4):1573–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2007;51(4):1253–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289–97.

    Article  CAS  PubMed  Google Scholar 

  87. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45(12):3487–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Perkhofer S, Lechner V, Lass-Florl C. European committee on antimicrobial susceptibility T. in vitro activity of Isavuconazole against aspergillus species and zygomycetes according to the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother. 2009;53(4):1645–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Verweij PE, Gonzalez GM, Wiedrhold NP, Lass-Florl C, Warn P, Heep M, et al. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother. 2009;21(3):272–81.

    Article  CAS  PubMed  Google Scholar 

  90. Castanheira M, Messer SA, Rhomberg PR, Dietrich RR, Jones RN, Pfaller MA. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia. 2014;178(1–2):1–9.

    Article  CAS  PubMed  Google Scholar 

  91. Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order. Antimicrob Agents Chemother. 2015;59(12):7735–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Kovanda LL, Desai AV, Lu Q, Townsend RW, Akhtar S, Bonate P, Hope WW. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study). Antimicrob Agents Chemother. 2016;60(8):4568–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–37.

    Article  CAS  PubMed  Google Scholar 

  94. Spellberg B, Brass EP. The VITAL study: case control studies are hypothesis-generating. Lancet Infect Dis. 2016;16(8):886.

    Article  PubMed  Google Scholar 

  95. Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61(10):1558–65.

    Article  CAS  PubMed  Google Scholar 

  96. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46(5):1581–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39(7):425–9.

    Article  CAS  PubMed  Google Scholar 

  98. Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother. 2003;47(11):3647–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003;51(1):45–52.

    Article  CAS  PubMed  Google Scholar 

  100. Van Cutsem J, Van Gerven F, Fransen J, Janssen PA. Treatment of experimental zygomycosis in Guinea pigs with azoles and with amphotericin B. Chemotherapy. 1989;35(4):267–72.

    Article  PubMed  Google Scholar 

  101. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46(4):1032–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother. 2007;51(7):2587–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Lass-Florl C, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, Fille M. The activities of antifungal agents against yeasts and filamentous fungi: assessment according to EUCAST methodology. Antimicrob Agents Chemother. 2008;52:3637–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol. 2008;12:1–7.

    Google Scholar 

  105. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50(2):658–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51(3):812–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27(12):1627–36.

    Article  CAS  PubMed  Google Scholar 

  108. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002;46(7):2310–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Rodriguez MM, Serena C, Marine M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine-disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52:3786–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE Jr, Spellberg B. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimocrob Agents Chemother. 2009;53:772–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Lekakis LJ, Lawson A, Prante J, Ribes J, Davis GJ, Monohan G, et al. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant. 2009;15(8):991–5.

    Article  PubMed  Google Scholar 

  112. Mousset S, Bug G, Heinz WJ, Tintelnot K, Rickerts V. Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation. Transpl Infect Dis. 2010;12(3):261–4.

    Article  CAS  PubMed  Google Scholar 

  113. Schlemmer F, Lagrange-Xelot M, Lacroix C, de La Tour R, Socie G, Molina JM. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant. 2008;42(8):551–2.

    Article  CAS  PubMed  Google Scholar 

  114. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61–5.

    Article  PubMed  Google Scholar 

  115. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. National Diabetes Fact Sheet, 2011. Atlanta: US Centers for Disease Control and Prevention; 2012.

    Google Scholar 

  117. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999;341(25):1906–12.

    Article  CAS  PubMed  Google Scholar 

  118. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016;22(9):811.e1–8.

    Article  CAS  Google Scholar 

  119. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, Edwards JE Jr, Douglas CM. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005;49(2):721–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49(2):830–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52(4):1556–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Ibrahim AS, Bryant R, Edwards JE, Spellberg B. Economic burden of mucormycosis in the United States: can a vaccine be cost-effective? Med Mycol. 2009;47(6):592–600.

    Article  PubMed  Google Scholar 

  123. Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, Skory CD, et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol. 2010;77(3):587–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol. 1994;47(10):1843–50.

    Article  PubMed  Google Scholar 

  125. Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006;58:1070–3.

    Article  CAS  PubMed  Google Scholar 

  126. Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006;50(11):3968–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53(7):3122–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris M, Perfect JR, Fredricks D, Brass EP. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study: A Randomized, Double-Blinded Placebo Controlled Trial. J Antimicrob Chemother. 2012;67:715–22.

    Article  PubMed Central  CAS  Google Scholar 

  129. Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, Kontoyiannis DP. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother. 2010;54(1):484–90.

    Article  CAS  PubMed  Google Scholar 

  130. Gil-Lamaignere C, Simitsopoulou M, Roilides E, Maloukou A, Winn RM, Walsh TJ. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis. 2005;191(7):1180–7.

    Article  CAS  PubMed  Google Scholar 

  131. Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004;23(8):769–73.

    Article  PubMed  Google Scholar 

  132. Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis. 1997;24(2):192–6.

    Article  CAS  PubMed  Google Scholar 

  133. Kullberg BJ, Anaissie EJ. Cytokines as therapy for opportunistic fungal infections. Res Immunol. 1998;149(4–5):478–88; discussion 515.

    Article  CAS  PubMed  Google Scholar 

  134. Grigull L, Beilken A, Schmid H, Kirschner P, Sykora KW, Linderkamp C, et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer. 2006;14(7):783–6.

    Article  PubMed  Google Scholar 

  135. John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect. 2005;11(7):515–7.

    Article  CAS  PubMed  Google Scholar 

  136. Busca A, Marmont F, Locatelli F, Limerutti G, Sorrentino MT, Barbui A, et al. Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. Mycoses. 2010;53(3):275–8.

    Article  PubMed  Google Scholar 

  137. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, et al. ICL670A: preclinical profile. Adv Exp Med Biol. 2002;509:185–203.

    Article  CAS  PubMed  Google Scholar 

  138. Rodriguez MM, Calvo E, Marine M, Pastor FJ, Fernandez-Ballart J, Guarro J. Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice. Antimicrob Agents Chemother. 2009;53(8):3569–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Los Angeles County+University of Southern California (LAC+USC) Medical Center, Los Angeles, CA, USA

    Brad Spellberg

  2. Division of Infectious Diseases, Keck School of Medicine at USC, Los Angeles, CA, USA

    Brad Spellberg

  3. Department of Hematology, Acute Leukemia and Stem Cell Transplantation Unit, University Hospital Gasthuisberg, K. U. Leuven, Leuven, Belgium

    Johan Maertens

Authors
  1. Brad Spellberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johan Maertens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brad Spellberg .

Editor information

Editors and Affiliations

  1. Clinical Associate Professor of Medicine, Texas Tech University Health Sciences Center El Paso, Paul L. Foster School of Medicine, El Paso, TX, USA

    Amar Safdar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Spellberg, B., Maertens, J. (2019). Mucormycosis. In: Safdar, A. (eds) Principles and Practice of Transplant Infectious Diseases. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-9034-4_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9034-4_34

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-9032-0

  • Online ISBN: 978-1-4939-9034-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation